Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > APP Announces FDA Acceptance of New Drug

May 10th, 2004

APP Announces FDA Acceptance of New Drug

Abstract:
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.

Source:
APP

Bookmark:

Related News Press

Nanomedicine

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013